Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma

Authors

  • Karina Karina Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia
  • Krista Ekaputri Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Johannes Albert Biben Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia https://orcid.org/0000-0002-5224-2146
  • Ratna Herawati Purwoko Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Tommy Partunggul Sibuea Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Sarah Listyo Astuti Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Anastasia Maria Loho Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Yuliardy Limengka Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Nelfidayani . Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Agustini S Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia https://orcid.org/0000-0003-4067-4408
  • Grady Krisandi Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Faculty of Medicine, University of Indonesia, Jakarta, Indonesia https://orcid.org/0000-0002-2016-8420
  • Azza Maryam Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Imam Rosadi Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Indonesia
  • Iis Rosliana Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Siti Sobariah Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Wismo Reja Subroto Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Irsyah Afini Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Tias Widyastuti Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Alfida Zakiyah Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Difky Ernanda Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Noor Aini Hayandra Lab, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Jusryanti . Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Sulaeha AD Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Sristin Indah Prestiani Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Indah Mustika Donna Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Habibi . Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia
  • Meyla Shinta Mutiara Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia

DOI:

https://doi.org/10.17532/jhsci.2021.1276

Keywords:

intravenous infusion, platelet-rich plasma, safety

Abstract

Introduction: Autologous platelet-rich plasma (PRP) has been a growing trend in the field of medicine due to its broad range of application and is considered safe from bloodborne diseases. Furthermore, various studies have tried to optimize the use of autologous PRP through various preparation protocols, including PRP activation. However, most of the studies available have not evaluated the safety for intravenous delivery of PRP, especially autologous activated PRP (aaPRP). Therefore, this study aimed to evaluate the safety of intravenous delivery of aaPRP.
Methods: Blood was drawn from each patient and aaPRP was isolated through calcium activation and light irradiation. Each aaPRP was administered intravenously to all patients. Adverse events were documented and analyzed.
Results: Six hundred eleven patients participated in this study with a total of 4244 aaPRP therapies. Quality control of autologous aaPRP showed no platelets present after both calcium activation and light irradiation. No adverse events such as allergic reaction, infection, and coagulation problems were observed on all patients over the course of the study.
Conclusion: Our results showed that intravenous administration of autologous aaPRP is safe even in patients with various pathological conditions.

Downloads

Download data is not yet available.

Published

2021-05-25

How to Cite

Karina, K., Ekaputri, K., Biben, J. A. ., Purwoko, R. H. ., Sibuea, T. P. ., Astuti, S. L. ., Loho, A. M. ., Limengka, Y., ., N., S, A. ., Krisandi, G. ., Maryam, A. ., Rosadi, I. ., Rosliana, I. ., Sobariah, S. ., Subroto, W. R. ., Afini, I. ., Widyastuti, T. ., Zakiyah, A. ., Ernanda, D. ., Aini, N. ., ., J., AD, S. ., Prestiani, S. I. ., Donna, I. M. ., ., H., & Mutiara, M. S. . (2021). Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma. Journal of Health Sciences. https://doi.org/10.17532/jhsci.2021.1276

Issue

Section

Research articles